- **RF Acquisition Corp II (RFAI)** has entered into a business combination agreement with **Nanyang Biologics Pte. Ltd. (NYB)**, with the goal of listing NYB on Nasdaq under the reserved ticker symbol "NYB".  **[2012807_20251002CN89192:0]** 
- The proposed transaction values NYB at approximately **$1.5 billion** in pre-transaction equity value.  **[2012807_20251002CN89192:1]** 
- NYB is an **AI-driven drug discovery and biotechnology company** utilizing its proprietary Vecura™ AI platform and DTIGN engine, with a pipeline of drug candidates targeting oncology, cardiovascular, and mental health, including the first-in-class oncology therapy **NB-A002**.  **[2012807_20251002CN89192:0]** **[2012807_20251002CN89192:1]** **[2012807_20251002CN89192:2]** 
- The closing of the transaction is expected in the **first or second quarter of 2026**, subject to shareholder approval and customary closing conditions.  **[2012807_20251002CN89192:2]**

RF Acquisition Corp II Enters Business Combination Agreement with Nanyang Biologics

- **RF Acquisition Corp II (RFAI)** entered into a business combination agreement with **Nanyang Biologics Pte. Ltd. (NYB)** on **October 2, 2025**, in a transaction that gives NYB approximately **$1.5 billion** in pre-transaction equity value.  **[2012807_0001829126-25-007836_rfacquisition2_ex99-1.htm:0]** **[2012807_0001829126-25-007836_rfacquisition2_ex99-1.htm:2]** 
- The proposed transaction aims to make NYB a publicly listed company on Nasdaq under the reserved ticker symbol **"NYB"**.  **[2012807_0001829126-25-007836_rfacquisition2_ex99-1.htm:0]** 
- NYB's existing shareholders will retain a majority of the combined company's outstanding shares and designate a majority of the director nominees for the board.  **[2012807_0001829126-25-007836_rfacquisition2_ex99-1.htm:0]** 
- The closing of the transaction is expected in the **first or second quarter of 2026**, subject to shareholder approval and customary closing conditions.  **[2012807_0001829126-25-007836_rfacquisition2_ex99-1.htm:2]**